- Home
- DXCM vs ONC Comparison
DXCM vs ONC Comparison
Compare DXCM & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXCM | ONC |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5B | 31.4B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXCM | ONC |
|---|---|---|
| Price | $64.72 | $318.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 11 |
| Target Price | $85.33 | ★ $380.45 |
| AVG Volume (30 Days) | ★ 3.6M | 191.2K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.18 | N/A |
| EPS | ★ 2.09 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.46 | $747.23 |
| Revenue Next Year | $12.31 | $15.78 |
| P/E Ratio | ★ $30.54 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.11 | $228.93 |
| 52 Week High | $89.07 | $385.22 |
Technical Indicators
Market Signals| Indicator | DXCM | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 58.95 |
| Support Level | $63.72 | $307.93 |
| Resistance Level | $69.18 | $320.35 |
| Average True Range (ATR) | 2.00 | 8.01 |
| MACD | 0.23 | 3.47 |
| Stochastic Oscillator | 66.95 | 80.19 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.